Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2006-03-21
2006-03-21
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
Reexamination Certificate
active
07014852
ABSTRACT:
The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention maybe used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens maybe effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.
REFERENCES:
patent: 4030995 (1977-06-01), Starkweather
patent: 4306020 (1981-12-01), Meiattini
patent: 2002/0037555 (2002-03-01), Chen
patent: 2002/0127216 (2002-09-01), Kiss
patent: WO 02/072136 (2002-09-01), None
U.S. Appl. No. 10/317,916, filed Dec. 12, 2002, Kiss.
Bell, G.I. and Polonsky, K.S., “Diabetes mellitus and genetically programmed defects in β-cell function.”Nature414, 788-791 (2001).
Mathis, D., Vence, L. and Benoist, C., “β-cell death during progression to diabetes.”Nature414, 792-798 (2001).
Saltiel, A.R., “New perspectives into the molecular pathogenesis and treatment of Type II diabetes,”Cell104, 517-529 (2001).
Zimmet, P., Alberti, K.G.M. and Shaw, J., “Global and societal implications of the diabetes epidemic,”Nature414, 782-787 (2001).
Moller, D.E., “New drug targets for Type II diabetes and the metabolic syndrome.”Nature414, 821-827(2001).
Ho, E. and Bray, T.M., “Antioxidants, NFκB activation, and diabetogenesis.”Proc. Soc. Exp. Biol. Med.222, 205-213 (1999).
[Saltiel, A.R. and Kahn, C.R., “Insulin signaling and the regulation of glucose and lipid metabolism.”Nature414, 799-806 (2001)].
U.K. Prospective Diabetes Study Group, “U.K Prospective Diabetes Study 16. Overview of 6 years' therapy of Type II diabetes: A progressive disease.”Diabetes44, 1249-1258 (1995).
Ryan, E.A., Lakey, J.R.T., Paty, B.W., Imes, S., Korbutt, G.S., Kneteman, N.M., Bigam, D., Rajotte, R.V. and Shapiro, A.M.J., “Successful islet transplantation: Continued insulin reserve provides long-term glycemic control.”Diabetes51, 2148-2157 (2002).
Clubb, J.S., Neale, F.C. and Posen, S., “The behavior of infused human placental alkaline phosphatase in human subjects.”J. Lab.&Clin. Med.66, 493-507 (1965).
She, Q.-B., Mukherjee, J.J., Chung, T. and Kiss, Z., “Placental alkaline phosphatase, insulin, and adenine nucleotides or adenosine synergistically promote long-term survival of serum-starved mouse embryo and human fetus fibroblasts.”Cellular Signalling12, 659-665 (2000).
She, Q.-B., Mukherjee, J.J., Huang, J.-S., Crilly, K.S. and Kiss, Z., “Growth factor-like effects of placental alkaline phosphatase in human and mouse embryo fibroblasts.”FEBS Lett.469, 163-167 (2000).
Rolin, B., Larsen, M.O., Gotfredsen, C.F., Deacon, C.F., Carr, R.D., Wilken, M. and Knudsen, L.B., “The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in a diabetic mice.”Am. J. Physiol. Endrocrinol. Metab.283, E745-E752 (2002).
Brownlee, M., “Biochemistry and molecular cell biology of diabetic complications.”Nature414, 813 (2001).
Chang, T.-C., Huang, S.-M., Huang, T.-M. and Chang, G.-G., “Human placenta alkaline phosphatase: An improved purification procedure and kinetic studies.”Eur. J. Biochem.209, 241-247 (1992).
Huang, D., Cheung, A.T., Parsons, J.T. and Bryer-Ash, M., “Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes.”J. Biol. Chem.277, 18151-18160 (2002).
Kottel, R.H. and Hanford, W.C., “Differential release of membrane-bound alkaline phosphatase isoenzymes from tumor cells by bromelain.”Biochem. Biophys. Methods2, 325-330 (1980).
Chang, G.-G., Shiao, M.-S., Lee, K.-R. and Wu, J.-J., “Modification of human placental alkaline phosphatase by periodate-oxidized 1,N6-ethenoadenosine monophosphate.”Biochem. J.272, 683-690 (1990).
Q.B.-She, J.J. Mukherjee, K.S. Crilly, and Z. Kiss, “α-antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines.”FEBS Letters473, 33-36 (2000).
Lyons, P.A., Armitage, N., Lord, C.J., Phillips, M.S., Todd, J.A., Peterson, L.B. and Wicker, L.S., “Mapping by Genetic Interaction: High resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse.”Diabetes50, 2633-2637 (2002).
Kaufman, D.L., Tisch, R., Sarvetnick, N., Chatenoud, L., Harrison, L.C., Haskins, K., Quinn, A., Sercarz, E., Herrath, M., Wegmann, D., Wen, L. and Zekzer, D., “Report from the 1stinternational NOD mouse T-cell workshop and the follow-up mini-workshop.”Diabetes50, 2459-2463 (2001).
Bonifacio, E., Atkinson, M., Eisenbarth, G., Serreze, D., Kay, T.W.H., Lee-Chan, E. and Singh, B., “International Workshop on lessons from animal models for human type 1 diabetes: Indentification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice.”Diabetes50, 2451-2458 (2001).
B.M. Spiegelman and J.S. Flier, “Obesity and the regulation of energy balance.”Cell104, 531-543 (2001).
F.M. Gregoire, “Adipocyte differentiation: From fibroblast to endocrine cell.”Exp. Biol. Med.226, 997-2001 (2001).
Brock et al., “Measurement of placental alkaline phosphatase in maternal plasma as an indicator of subsequent low birthweight outcome”,British Journal of Obstetrics and Gynaecology,Jan. 1988, vol. 95, pp. 769-83.
PCT International Search Report, Mailed Apr. 21, 2004 (7 pages).
Faegre & Benson LLP
Witz Jean C.
Zoltan Laboratories
LandOfFree
Alkaline phosphatase to induce weight loss or to reduce... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkaline phosphatase to induce weight loss or to reduce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkaline phosphatase to induce weight loss or to reduce... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571141